Three American universities, Auburn, Temple and Yale School of Public Health, are conducting a clinical trial entitled “EVOO for Brain Health” on the effect of high phenolic olive oil on genetic and metabolic changes in healthy individuals with a family history of the disease Alzheimer’s.
The extra virgin olive oil that will be used exclusively by the researchers of the American universities is the “Plus Health Green Evoo” of the “biological olive groves of Sakellaropoulos,” with a high content of oleocanthal.
“Plus Health Green Evoo” extra virgin olive oil is a multivariate olive oil of specialised production, derived from five different olive varieties, with a content of 977 mg/Kg of oleocanthal, a percentage that exceeds by 720% the average of international olive oil sampling samples (135 mg/ Kg), which were also included in a study, also carried out at Davis University, in California, United States of America,” Mr G.Sakellaropoulos told AMNA.
“Scientific research and synergies have been at our core since our inception. In this context, multi-year clinical studies and research projects are already being carried out with our organic olive oils and table olives at Harvard University’s School of Public Health, Yale University’s School of Public Health, as well as at the Athens School of Pharmacy of EKPA”, he added.
How will the research be done?
The new research project begins alongside a clinical trial at Auburn University to evaluate the effect of high phenolic olive oil – mainly oleocanthal – in healthy people who have a family history of Alzheimer’s disease, which is usually associated with a genetic predisposition.
The aim of the research is to the effect of adding extra virgin olive oil to the daily diet of the volunteers, as it has not been investigated to date whether, with daily consumption of extra virgin oleocanthal olive oil, people with a genetic predisposition to Alzheimer’s disease are protected.
About 50 million people worldwide have Alzheimer’s
Alzheimer’s is a chronic neurodegenerative disease that begins slowly and accelerates over time. It is incurable and fatal, accounting for 60% to 70% of dementia cases.
In the United States, six million people live with the disease. That number is projected to rise to 13 million by 2050, according to the Alzheimer’s Association of America, and an estimated 50 million people worldwide are living with the disease today.
The EVOO for the Brain Health clinical trial has already been approved by Auburn University’s Institutional Review Board (IRB) and is expected to be completed at the end of 2024, as volunteers will be tested with specialized analyses twice a year.
Who Makes Up the Research Team
The three-university research team that will collaborate on this important clinical trial for human health consists of Professor and Researcher of Neuropharmacology Dr. Amal Kaddoumi, Department of Drug Discovery and Development, Harrison College of Pharmacology, University Auburn. Professor of Neurosciences Dr. Domenico Praticò, MD, director of the Temple University Alzheimer’s Center, as well as Dr. Tassos K. Kyriakides, researcher in Epidemiology, Biostatistics and Clinical Studies, Assistant Professor at the Yale University School of Public Health, America.
Also collaborating on this project are Dr. Annie Kirby, Darren Beck and Joshua Hollingsworth of Auburn University’s Edward Via College of Osteopathic Medicine (VCOM).
The research project titled ‘EVOO for Brain Health’? has registration number NCT05929924 in the ClinicalTrials.gov scientific database of clinical trials of the United States of America and 220 countries, maintained by the National Library of Medicine (NLM) at the National Institutes of Health, NIH) of the USA.